Background
==========

Epidemiological studies have showed that incidence and mortality of rectal cancer are increasing year by year in China, and it seriously threatens the lives of Chinese people \[[@b1-medscimonit-26-e920604]\]. Besides, most rectal cancers at diagnosis are at a locally advanced stage with or beyond serosal invasion (T3 or T4 stage). Surgery along with chemoradiotherapy and immunotherapy remains the main treatments for these patients.

With the rapid development of laparoscopic instruments and techniques, laparoscopic rectal surgery (LRS) has been widely used for treating rectal cancer with minimal trauma and rapid recovery \[[@b2-medscimonit-26-e920604]\]. Clear surgical field and full exposure of anatomical structure enables LRS to achieve curative resection for rectal cancer, to reduce surgical trauma and improve quality of life after surgery \[[@b3-medscimonit-26-e920604]\]. Despite these advantages, complications after LRS are still inevitable. Previous studies have reported that the incidence rate of postoperative complications is 20% to 30% for rectal cancer, incidence rate of serious complications is 5% to 12%, and the mortality is about 2% \[[@b4-medscimonit-26-e920604],[@b5-medscimonit-26-e920604]\]. Besides, some situations including obesity, male gender, low location of tumor, and advanced stage of cancer likely impose increased difficulty for LRS for rectal cancer, which leads to prolonged operative time, more blood loss, and increased risk of postoperative complications. Yasui et al. reported that 25.9% of patients had postoperative complications after LRS, and that tumor size (≥4 cm) and tumor stage (T4) were independent risk factors for postoperative complications, which suggests that it is very important to select appropriate patients for LRS \[[@b6-medscimonit-26-e920604]\].

Clavien-Dindo system has been widely used to classify postoperative complications. Clavien-Dindo III/IV complications that require re-operation, endoscopic or radiological intervention are defined as severe complications \[[@b7-medscimonit-26-e920604]\] that always lead to disastrous outcomes like organ failure or even death as well as significantly high medical costs. In this study, we summarized the clinical data of the patients with T3 or T4 rectal cancer who underwent LRS for rectal cancer. In addition, we also explored potential risk factors for postoperative severe complications to ensuring safety of LRS for T3 or T4 rectal cancer patients.

Material and Methods
====================

Patients
--------

From February 2012 to February 2017, clinical data from 287 patients who were diagnosed as T3 or T4 rectal cancer and underwent LRS in the First Affiliated Hospital of Chinese University of Science and Technology (Anhui Provincial Hospital) were retrospectively collected. According to the 8th TNM staging system (American Joint Committee on cancer, AJCC), T3 or T4 rectal cancer is defined as tumor penetrates into or beyond serosal layer of rectum. This study was approved by our ethics committee, and the study complied with the Helsinki declaration.

Inclusion criteria of patients were as follows: 1) patients were pathologically diagnosed with rectal cancer, and tumor lesion was within 15 cm from the anus; 2) preoperative magnetic resonance imaging (MRI) examination indicated that TNM stage of rectal cancer were T3N0--2M0, or T4N0--2M0, which was further confirmed by postoperative pathological examination; 3) patients underwent radical LRS for rectal cancer, including Dixon, Miles, or Hartmann procedure; 4) clinical records were complete and available. Exclusion criteria of this study included: 1) clinical data was missing and incomplete; 2) patients had a history of malignant tumors; 3) emergency surgery due to massive bleeding, obstruction, or perforation.

Perioperative assessment and management
---------------------------------------

### Perioperative assessment

All patients underwent a preoperative evaluation to determine whether they could successfully undergo surgery, including physical examination, colonoscopy with tumor biopsy, MRI, and thoraco-abdominopelvic computed tomography (CT) scan. The following clinical data were collected: 1) perioperative data, including age, gender, American Society Anesthesiologist (ASA) score, distance from the low verge of tumor to anus, cardiovascular disease, respiratory disease, cerebrovascular disease, hypertension, diabetes, previous abdominal surgery, neoadjuvant radiochemotherapy. 2) Preoperative laboratory parameters, including white blood cell count (WBC; 10^9^/L), neutrophil count (10^9^/L), albumin (g/L), and hemoglobin (Hb; g/L). 3) Intraoperative parameters, including operative time, estimated blood loss, types of operations (Dixon, Miles, Hartmann), stoma (yes or no), and combined organ resection (yes or no). 4) Postoperative data, including pathological assessment using 8th TNM system (AJCC), and postoperative hospital stay defined as period from surgery to discharge and severe complication.

### Perioperative management

Mechanical bowel preparation with oral antibiotics was routinely conducted for patients without obstruction. Prophylactic antibiotics were administrated within 30 minutes via intravenous perfusion before surgery, and stopped within 48 hours after surgery. Patients were required to walk (get out of bed) at day 2 and allowed liquid diet at day 3 after surgery. All patients were given intravenous nutrition until resumption of semiliquid diet.

Surgical technique
------------------

Surgical procedures for LAR have been described in a previous study \[[@b8-medscimonit-26-e920604]\]. In brief, after success of general anesthesia, 5 trocars were inserted into abdominal cavity. Laparoscopic exploration was conducted to determine whether there was intraperitoneal metastasis. A standardized surgical technique termed total anatomical dissection was adopted. The rectum along with its fascial layers was dissected in the bloodless plane. The splenic flexure was mobilized if necessary. The inferior mesenteric vein was ligated at the lower border of the pancreas, and inferior mesenteric artery was ligated at initial part. A total mesorectal excision (TME) was performed in patients with middle- and lower-third tumor; whereas the perirectal fat was divided and ligated 5 cm below the tumor for patients with upper-third tumor. Prophylactic ileum stoma was created in patients with tumor under peritoneal reflection.

Definition of postoperative severe complications
------------------------------------------------

Severity of postoperative complications within 30 days after surgery was evaluated using the Clavien-Dindo scale ([Table 1](#t1-medscimonit-26-e920604){ref-type="table"}). Clavien-Dindo III/IV complications requiring surgical, endoscopic or radiological interventions were defined as severe complications.

Statistical analysis
--------------------

All statistical analyses were performed using SPSS^®^ version 20.0 software (SPSS, IBM). Categorical variables were present as percentage, whereas continuous variables were transformed into categorical variables using 75% quartile of interquartile ranges as cut-value, and then all categorical data were compared using chi-square test. Multivariate logistic regression was conducted based on the variables in the univariate analysis (*P*\<0.10) and on the factors clinically related to the sever complications after surgery. *P*-value \<0.05 was considered statistically significant.

Results
=======

Characteristics of patients
---------------------------

A total of 287 patients were enrolled in this study, including 170 males (59.2%) and 117 females (40.8%); basic information for these patients is listed in [Table 2](#t2-medscimonit-26-e920604){ref-type="table"}. Among these patients, 211 patients (73.5%) were \<71 years old, and 76 patients (26.5%) were ≥71 years old; 86.8% of all study patients (249 patients) were classified as ASA I/II and 13.2% (38 patients) were classified as ASA III. A total of 12 patients received neoadjuvant radiochemotherapy. Proportions of patients with upper, middle, and lower rectal tumors were 19.5%,43.2%, and 37.3%, respectively.

Intraoperative and pathological outcomes
----------------------------------------

Intraoperative parameters are shown in [Table 3](#t3-medscimonit-26-e920604){ref-type="table"}. Operative time, intraoperative blood loss, proportions of surgical procedures were not statistically different between 2 group. We noted that, although no statistical significance, patients with severe complications had lower proportion of stoma than patients without severe complications (*P*=0.09).

Information for pathological outcomes and postoperative recovery are shown in [Table 4](#t4-medscimonit-26-e920604){ref-type="table"}. There were no statistical significances of number of lymph node harvested, positive lymph node, tumor size, or TNM stage between patients with or without severe complications. As expected, patients with severe complications had prolonged postoperative feeding and hospital time than patients without severe complication.

Severe complications
--------------------

A total of 18 patients (6.25%) had severe complications. According to the Clavien-Dindo staging scale, 15 patients were classified as grade III and 3 cases were grade IV. Detail information of severe complications for these patients is shown in [Supplementary Table 1](#s1-medscimonit-26-e920604){ref-type="supplementary-material"}. There was no death in all patients.

Univariate analysis of severe complications and Postoperative situation
-----------------------------------------------------------------------

Univariate analysis showed that male patients, high preoperative WBC, diabetes, pulmonary dysfunction, and the distance of tumor to anal verge were associated with severe complications after LRS (*P*\<0.05); whereas prophylactic stoma likely contributed to the decreased risk of severe complications, although it did not reach statistical significance (*P*=0.09). In contrast, other variates including age, hypertension, cardiac dysfunction, cerebral disease, ASA classification, TNM stage, etc, were not statistically significant (*P*\>0.05). The details are shown in [Table 2](#t2-medscimonit-26-e920604){ref-type="table"}[](#t3-medscimonit-26-e920604){ref-type="table"}--[4](#t4-medscimonit-26-e920604){ref-type="table"}.

Multivariate logistic regression analysis of severe complications
-----------------------------------------------------------------

Multivariate logistic regression analysis was performed to analyze the factors that were associated with postoperative severe complications in the univariate analysis (*P*\<0.1) and preoperative white blood cells (OR=6.11, *P*=0.02), diabetes (OR=17.52, *P*=0.001) and pulmonary dysfunction (OR=11.20, *P*=0.01) were independent risk factors for severe complications after laparoscopic surgery for rectal cancer ([Table 5](#t5-medscimonit-26-e920604){ref-type="table"}).

Discussion
==========

Surgery is the most effective approach for treatment of rectal cancer. However, postoperative complication still remains a problem that surgeons have to face. Published studies have reported that the incidence of postoperative complications ranged from 20% to 30%, of which the incidence of severe complications ranged from 5% to 12% \[[@b4-medscimonit-26-e920604],[@b5-medscimonit-26-e920604]\]. In this study, univariate analysis of clinical data from 287 patients with T3 or T4 rectal cancer showed that male gender, high WBC, diabetes, pulmonary dysfunction, and low site of cancer contributed to the increased risk of severe postoperative complications. Multivariate logistic regression analysis further indicated that preoperative high WBC, diabetes, and pulmonary dysfunction were independent risk factors for postoperative severe complications for these patients.

In China, most patients diagnosed as T3 or T4 rectal cancer \[[@b9-medscimonit-26-e920604]\], which is characterized by large tumor size and involvement of rectal fascial layers, and which leads to significantly difficult dissection in the bloodless plane as well as more technically challenging for laparoscopic surgery than early rectal cancer. The rate for severe complication after laparoscopic surgery for advanced-stage rectal cancer has been reported to be 22.5%, whereas the rate for early-stage rectal cancer was 2% \[[@b10-medscimonit-26-e920604],[@b11-medscimonit-26-e920604]\], which suggested that risk factors of severe complications for advanced rectal cancer is different from that for early-staged rectal cancer after laparoscopic surgery.

There were several important observations of this study. Firstly, we found that male patients were at higher risk of severe complications after laparoscopic surgery for T3 or T4 rectal cancer than female patients, which was in line with previous studies \[[@b12-medscimonit-26-e920604]--[@b14-medscimonit-26-e920604]\]. Saadat et al. reported that male gender and chronic pulmonary diseases contributed to reoperation after surgery for rectal cancer \[[@b15-medscimonit-26-e920604]\]. Another study conducted by Kang et al. suggested that male gender was an independent risk factor for postoperative complication after robotic rectal cancer surgery \[[@b16-medscimonit-26-e920604]\]. In addition, male gender was also identified as a risk factor for postoperative complication for transanal total mesorectal excision (TaTME) for rectal cancer \[[@b17-medscimonit-26-e920604]\]. These evidences indicated that male status increases postoperative complication of rectal cancer surgery regardless of surgical approach. This may be related to pelvic stenosis in males, which leads to small surgical space, difficulties in surgical separation, dissection, and anastomosis. Increased difficulty of surgical manipulation also causes the damage of blood vessels surrounding rectum, which leads to disrupted blood supply to anastomosis and increase the risk of postoperative anastomotic leakage \[[@b18-medscimonit-26-e920604]\].

The second important finding of this study was that diabetes was an independent risk factor for laparoscopic surgery after rectal cancer. Diabetes is one of the most common chronic and metabolic diseases that not only causes neurological and vascular diseases, but it is also closely related to occurrence and prognosis of cancer \[[@b19-medscimonit-26-e920604],[@b20-medscimonit-26-e920604]\]. In this study, all diabetic patients were monitored for blood glucose pre- and post-surgery. Endocrinologist consulted to control blood glucose between 8 and 10 mmol/L before and after surgery. However, not every patient is tested for HbA1C level before surgery. Both univariate analysis and multivariate logistic regression analysis suggested that diabetes was an independent risk factor for severe complications after laparoscopic rectal surgery, which was consistent with the results reported by Penna et al. \[[@b17-medscimonit-26-e920604]\]. Previous studies have reported that hyperglycemia caused by diabetes significantly increased risk of postoperative complications in patients with rectal cancer \[[@b21-medscimonit-26-e920604],[@b22-medscimonit-26-e920604]\]. This may be related to poor tissue healing ability of diabetic patients \[[@b23-medscimonit-26-e920604]\]. In addition, diabetic patients are prone to arteriosclerosis, which causes poor blood supply to the anastomosis and affects healing of the anastomosis. Meanwhile, the risk of incision infection in diabetic patients far exceeds that of non-diabetics.

The third important finding of this study was that pulmonary dysfunction was an independent risk factor for postoperative severe complications after laparoscopic rectal surgery, which was in line with the report by Alves et al. \[[@b24-medscimonit-26-e920604]\]. In laparoscopic surgery, it is necessary to maintain a certain carbon dioxide pneumoperitoneum. However, blood gas analysis is performed only when the patient's vital signs are not stable, so blood gas monitoring is not performed for all patients. The main consideration is the effect of carbon-dioxide pneumoperitoneum on the respiratory system during laparoscopic surgery which induces systemic oxidative stress. In addition, hypercarbia and acidosis can occur because of ventilation-perfusion mismatch caused by impaired gas exchange due to increased intra-abdominal pressure or absorption of insufflated CO~2~, which promotes the produce of serum oxidative stress markers and leads to altered hemodynamics\[[@b25-medscimonit-26-e920604]--[@b27-medscimonit-26-e920604]\]. In our research, of the 15 patients (5.2%) with preoperative pulmonary dysfunction, 4 patients developed severe complications after surgery. The difference was statistically significant (*P*=0.008). The difference may be due to decrease in tolerance to pneumoperitoneum and surgery in patients with preoperative pulmonary dysfunction. Therefore, sufficient preoperative assessment and active control of preoperative comorbidity are important to reduce the occurrence of surgical complications.

At last, both univariate and multivariate analysis showed that high preoperative white blood cell (WBC) count was associated with increased risk of postoperative severe complication after laparoscopic rectal cancer surgery in our study. WBC count is a non-specific marker for inflammatory reaction, and high preoperative WBC count indicates that the body is in an inflammatory and immune stress state, and will have poor resistance to surgical trauma and infection. Preoperative inflammation is not only associated with high risk of postoperative complication, but also with poor prognosis \[[@b28-medscimonit-26-e920604]--[@b30-medscimonit-26-e920604]\]. Moyes et al. reported that elevated preoperative white cell count (*P*\<0.05) were independently associated with increased risk of developing a postoperative infection \[[@b31-medscimonit-26-e920604]\]. Another recent study showed that increased preoperative WBC count was independently associated with anastomotic leak after esophagectomy \[[@b32-medscimonit-26-e920604]\]. In aforementioned analysis, the authors estimate that for every 3000/μL increase in the preoperative WBC count, the associated risk increased by 32% \[[@b32-medscimonit-26-e920604]\].

Some limitations should be acknowledged here. First, clinical data used in this study were retrospectively collected, which might cause bias. To avoid this bias, the data were inter-checked by 2 authors (LL and DL). Second, neoadjuvant chemoradiotherapy is currently the standard treatment for locally advanced rectal cancer and has been recommended by guidelines \[[@b33-medscimonit-26-e920604],[@b34-medscimonit-26-e920604]\]. Although previous studies have reported that neoadjuvant chemoradiotherapy increased the risk of severe complications \[[@b13-medscimonit-26-e920604],[@b35-medscimonit-26-e920604]--[@b37-medscimonit-26-e920604]\], we could get reach this conclusion, because few patients received neoadjuvant chemoradiotherapy.

Conclusions
===========

In summary, this study suggested that preoperative high WBC count (≥6.9×10^9^/L), diabetes, and pulmonary dysfunction were independent risk factors for severe complications after laparoscopic surgery for T3 or T4 rectal cancer. Prospective high-quality studies are required to confirm our findings in the future.

Supplementary Data
==================

###### 

Details of severe postoperative complications for 18 patients.

  No of patients   Age   Gender   Details of complications                        Tumor location   Treatment
  ---------------- ----- -------- ----------------------------------------------- ---------------- -------------------------------------------------
  Patient 1        54    Male     Anastomotic leakage                             Middle           Reoperation; transverse colostomy
  Patient 2        57    Male     Anastomotic leakage                             Middle           Reoperation; transverse colostomy
  Patient 3        59    Male     Anastomotic leakage                             Middle           Conservative treatment; drainage and irrigation
  Patient 4        60    Female   Cerebral infarction                             Low              Conservative treatment
  Patient 5        60    Male     Anastomotic leakage                             High             Conservative treatment; drainage and irrigation
  Patient 6        41    Male     Anastomotic leakage                             Low              Conservative treatment; drainage and irrigation
  Patient 7        55    Female   Postoperative Bleeding                          Middle           Conservative treatment
  Patient 8        69    Male     Ileus and renal dysfunction                     Middle           Conservative treatment
  Patient 9        76    Male     Postoperative bleeding                          Middle           Reoperation; hemostasis
  Patient 10       64    Male     anastomotic leakage                             High             Reoperation and ileostomy
  Patient 11       70    Male     Wound infection                                 High             Secondary incision
  Patient 12       55    Male     Anastomotic leakage                             Middle           Conservative treatment; drainage and irrigation
  Patient 13       78    Male     Abdominal infection and pulmonary dysfunction   High             Conservative treatment; drainage and irrigation
  Patient 14       73    Male     Postoperative bleeding                          Middle           Conservative treatment
  Patient 15       68    Male     Anastomotic leakage                             Middle           Reoperation and ileostomy
  Patient 16       66    Male     Intestinal obstruction                          Middle           Reoperation and small intestine resection
  Patient 17       78    Female   Anastomotic leakage                             Middle           Reoperation and ileostomy
  Patient 18       51    Male     Postoperative bleeding                          Middle           Reoperation; hemostasis
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###### 

Clavien-Dindo scale for definition of severe complication.

  Clavien-Dindo classification   
  ------------------------------ -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Grade I                        Any deviation from the normal postoperative course without the need for pharmacological treatment or surgical, endoscopic and radiological interventions. Appropriate treatments are allowed: antiemetics, antipyretics, analgesics, diuretics, electrolytes, and physical therapy. Wound infections that are open at the bed are also part of this class
  Grade II                       Requiring pharmacological treatment with drugs other than such allowed for grade I complications. Including need for blood transfusions and total parenteral nutrition
  Grade III                      Requires surgery, endoscopy or radiological intervention
  Grade IIIa                     Intervention not under general anesthesia
  Grade IIIb                     Intervention under general anesthesia
  Grade IV                       Life-threatening complication (including CNS complications) and requiring IC/ICU-management
  Grade IVa                      Single organ dysfunction (including dialysis)
  Grade IVb                      Multiple organ dysfunction
  Grade V                        Death

###### 

Basic characteristics of patients.

  Variables                           Total (n, %)   Group A (n, %)[\*](#tfn1-medscimonit-26-e920604){ref-type="table-fn"}   Group B (n, %)[\*](#tfn1-medscimonit-26-e920604){ref-type="table-fn"}   Test value   *P* value
  ----------------------------------- -------------- ----------------------------------------------------------------------- ----------------------------------------------------------------------- ------------ -----------
  Total patients                      287            269                                                                     18                                                                                   
  Gender                                                                                                                                                                                             χ^2^=4.62    0.045
   Male                               170 (59.2)     155 (57.6)                                                              15 (83.3)                                                                            
   Female                             117 (40.8)     114 (42.4)                                                              3 (16.7)                                                                             
  Age (years)                                                                                                                                                                                        χ^2^=0.18    0.80
   \<71                               211 (73.5)     197 (73.2)                                                              14 (77.8)                                                                            
   ≥71                                76 (26.5)      72 (26.8)                                                               4 (22.2)                                                                             
  Preoperative WBC (10^9^/L)                                                                                                                                                                         χ^2^=6.11    0.02
   \<6.9                              214 (74.6)     205 (76.2)                                                              9 (50.0)                                                                             
   ≥6.9                               73 (25.4)      64 (23.8)                                                               9 (50.0)                                                                             
  Preoperative neutrophil (10^9^/L)                                                                                                                                                                  χ^2^=2.07    0.15
   \<4.41                             216 (75.3)     205 (76.2)                                                              11 (61.1)                                                                            
   ≥4.41                              71 (24.7)      64 (23.8)                                                               7 (38.9)                                                                             
  Preoperative hemoglobin (g/L)                                                                                                                                                                      χ^2^=0.01    1.00
   \<138                              210 (73.2)     197 (73.2)                                                              13 (72.2)                                                                            
   ≥138                               77 (26.8)      72 (26.8)                                                               5 (27.8)                                                                             
  Preoperative albumin (g/L)                                                                                                                                                                         χ^2^=0.63    0.41
   \<43.4                             214 (74.6)     202 (75.1)                                                              12 (66.7)                                                                            
   ≥43.4                              73 (25.4)      67 (24.9)                                                               6 (33.3)                                                                             
  ASA classification                                                                                                                                                                                 χ^2^=0.08    1.00
   1--2                               249 (86.8)     233 (86.6)                                                              16 (88.9)                                                                            
   3                                  38 (13.2)      36 (13.4)                                                               2 (11.1)                                                                             
  Distance from the anus (cm)                                                                                                                                                                        χ^2^=6.05    0.049
   \>10 (high)                        56 (19.5)      52 (19.4)                                                               4 (22.2)                                                                             
   5--10 (middle)                     124 (43.2)     112 (41.6)                                                              12 (66.7)                                                                            
   ≤5 (low)                           107 (37.3)     105 (39.0)                                                              2 (11.1)                                                                             
  Comorbidities                                                                                                                                                                                                   
   Hypertension                       71 (24.7)      65 (24.2)                                                               6 (33.3)                                                                χ^2^=0.76    0.40
   Diabetes                           29 (10.1)      22 (8.2)                                                                7 (38.9)                                                                χ^2^=17.52   0.001
   Pulmonary dysfunction              15 (5.2)       11 (4.1)                                                                4 (22.2)                                                                χ^2^=11.20   0.01
   Heart dysfunction                  27 (9.4)       25 (9.3)                                                                2 (11.1)                                                                χ^2^=0.07    0.68
   Cerebral diseases                  12 (4.2)       11 (4.1)                                                                1 (5.6)                                                                 χ^2^=0.09    0.55
   Previous abdominal surgery         39 (13.6)      36 (13.4)                                                               3 (16.7)                                                                χ^2^=0.16    0.72
   Neoadjuvant radiochemotherapy      12 (4.2)       11 (4.1)                                                                1 (5.6)                                                                 χ^2^=0.09    0.55

Group A was patients with non-severe complications, whereas Group B was patients with severe complications.

###### 

Intraoperative outcomes.

  Variables                   Total (n, %)   Group A (n, %)[\*](#tfn2-medscimonit-26-e920604){ref-type="table-fn"}   Group B (n, %)[\*](#tfn2-medscimonit-26-e920604){ref-type="table-fn"}   Test value   *P* value
  --------------------------- -------------- ----------------------------------------------------------------------- ----------------------------------------------------------------------- ------------ -----------
  Total patients              287            269                                                                     18                                                                                   
  Surgical procedures                                                                                                                                                                        χ^2^=3.78    0.15
   Dixon                      199 (69.3)     183 (68.0)                                                              16 (88.9)                                                                            
   Miles                      68 (23.7)      67 (24.9)                                                               1 (5.55)                                                                             
   Hartmann                   20 (7.0)       19 (7.1)                                                                1 (5.55)                                                                             
   Stoma                      152 (53.0)     146 (54.2)                                                              6 (33.3)                                                                χ^2^=2.97    0.09
   Combined organ resection   6 (2.1)        6 (2.2)                                                                 0 (0.0)                                                                 χ^2^=0.41    1.00
  Operative time                                                                                                                                                                             χ^2^=0.70    0.41
   \<221 min                  215 (74.9)     203 (75.5)                                                              12 (66.7)                                                                            
   ≥221 min                   72 (25.1)      66 (24.5)                                                               6 (33.3)                                                                             
  Estimated blood loss                                                                                                                                                                       χ^2^=2.52    0.14
   \<100 mL                   109 (38.0)     99 (36.8)                                                               10 (55.6)                                                                            
   ≥100 mL                    178 (62.0)     170 (63.2)                                                              8 (44.4)                                                                             

Group A was patients with non-severe complications, whereas Group B was patients with severe complications.

###### 

Pathological outcomes and postoperative recovery.

  Variables                                     Total (n, %)   Group A (n, %)[\*](#tfn3-medscimonit-26-e920604){ref-type="table-fn"}   Group B (n, %)[\*](#tfn3-medscimonit-26-e920604){ref-type="table-fn"}   Test value   *P* value
  --------------------------------------------- -------------- ----------------------------------------------------------------------- ----------------------------------------------------------------------- ------------ -----------
  Total patients                                287            269                                                                     18                                                                                   
  Number of lymph node                                                                                                                                                                                         χ^2^=0.00    1.00
   \<11                                         207 (72.1)     194 (72.1)                                                              13 (72.2)                                                                            
   ≥11                                          80 (27.9)      75 (27.9)                                                               5 (27.8)                                                                             
  Number of metastatic lymph node                                                                                                                                                                              χ^2^=0.38    0.79
   \<3                                          205 (71.4)     191 (71.0)                                                              14 (77.8)                                                                            
   ≥3                                           82 (28.6)      78 (29.0)                                                               4 (22.2)                                                                             
  Tumor size (cm)                                                                                                                                                                                              χ^2^=0.18    0.79
   \<5                                          204 (71.1)     192 (71.4)                                                              12 (66.7)                                                                            
   ≥5                                           83 (28.9)      77 (28.0)                                                               6 (33.3)                                                                             
  Differentiation                                                                                                                                                                                              χ^2^=0.08    1.00
   Moderate/high                                215 (74.9)     201 (74.7)                                                              14 (77.8)                                                                            
   Low                                          72 (25.1)      68 (25.1)                                                               4 (22.2)                                                                             
  TNM stage, n (%)                                                                                                                                                                                             χ^2^=2.76    0.14
   II                                           153 (53.3)     140 (52.0)                                                              13 (72.2)                                                                            
   III                                          134 (46.7)     129 (48.0)                                                              5 (27.8)                                                                             
  Postoperative feeding time (days, mean±SD)    4.14±2.27      3.94±1.73                                                               7.11±5.41                                                               t=73.43      0.00
  Postoperative hospital stay (days, mean±SD)   11.21±6.41     9.93±3.00                                                               30.22±11.96                                                             t=140.62     0.00

Group A was patients with non-severe complications, whereas Group B was patients with severe complications.

SD -- standard deviation.

###### 

Multivariate logistic regression analysis of severe complications after laparoscopic surgery for T3 or T4 rectal cancer.

  Variates                                       Regression coefficient   Standard error   Wald values   OR value              *P* value
  ---------------------------------------------- ------------------------ ---------------- ------------- --------------------- -----------
  Gender (Male *vs.* Female)                     1.13                     0.71             2.54          3.10 (0.77--12.45)    0.11
  Preoperative WBC (≥6.9 *vs.* \<6.9, 10^9^/L)   1.71                     0.64             7.14          5.54 (1.58--19.45)    0.008
  Diabetes (yes *vs.* no)                        2.57                     0.70             13.44         13.07 (3.31--51.67)   0.000
  Pulmonary dysfunction (yes *vs.* no)           2.05                     0.78             6.93          7.75 (1.69--35.63)    0.008
  Surgical procedures                                                                                                          
   Dixon                                                                                   1.20          1                     0.55
   Miles                                         −0.59                    1.41             0.18          0.56 (0.04--8.72)     0.68
   Hartmann                                      −1.42                    1.35             1.11          0.24 (0.02--3.39)     0.29
   Diverting stoma (yes*vs*. no)                 −0.03                    0.69             0.002         0.97 (0.25--3.74)     0.96
   Estimated blood loss (≥100 *vs.* \<100 mL)    −0.49                    0.59             0.70          0.61 (0.19--1.95)     0.40
  Tumor distance (cm)                                                                                                          
   \>10                                                                                    1.41          1                     0.50
   5--10                                         0.73                     0.72             1.04          2.07 (0.51--8.43)     0.31
   ≤5                                            −0.08                    1.18             0.004         0.93 (0.09--9.25)     0.95
  TNM stage (III *vs.* II)                       −0.76                    0.61             1.58          0.47 (0.14--1.53)     0.21
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